{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that I2020T mutant LRRK2 exhibits higher susceptibility to intracellular degradation, leading to impaired protective effects against apoptosis and contributing to neurodegeneration.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly links the I2020T mutation's degradation susceptibility to neurodegeneration, defining a clear disease mechanism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses apoptosis assays and protein degradation analysis to model the pathogenic mechanism of I2020T LRRK2.",
          "judgment": "Yes",
          "reasoning": "The assays (apoptosis and degradation analysis) directly model the disease mechanism described in Step 1, which involves protein stability and neurodegeneration.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study compares I2020T with wild-type LRRK2, uses proteolysis inhibitors to recover protein levels, and knocks down WT LRRK2 to assess protectivity.",
          "judgment": "Yes",
          "reasoning": "Basic controls (wild-type vs. mutant) and variant-specific manipulations (proteolysis inhibitors, knockdown) were used, satisfying Step 3a and 3c requirements.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The paper does not explicitly report statistical analyses (p-values, OddsPath) but demonstrates functional differences between I2020T and wild-type LRRK2.",
          "judgment": "No",
          "reasoning": "Statistical analyses (e.g., p-values, OddsPath) are not explicitly reported, so the study proceeds to Sub-step 4b.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study uses wild-type and knockdown controls but does not quantify the number of benign/pathogenic variant controls used.",
          "judgment": "No",
          "reasoning": "The paper lacks explicit reporting of the total number of benign/pathogenic variant controls used in the study, making it impossible to apply the 10/11 threshold rule.",
          "next_step_or_outcome": "Assign Max PS3_supporting"
        }
      ],
      "strength": {
        "type": "PS3",
        "category": "supporting",
        "explanation": "The study demonstrates functional differences (impaired apoptosis protection) between I2020T and wild-type LRRK2, with controls and mechanistic links to neurodegeneration. However, statistical analyses (e.g., p-values, OddsPath) are not explicitly reported, limiting the strength to 'supporting' under ACMG guidelines."
      }
    }
  ]
}